Skeletal Muscle Myokine Response to Acute Eccentric Exercise

November 4, 2024 updated by: University of Manitoba
The purpose of this study is to evaluate the acute local skeletal muscle inflammatory response to thigh muscle (quadriceps) eccentric muscle actions. Eccentric muscle actions occur when the muscle is lengthening as it contracts. This is a pilot project to assess the degree of inflammatory biomarkers, called myokines, that are released locally in skeletal muscle tissue after an acute bout of resistance-exercise using a resistance-exercise machine called an isokinetic dynamometer.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The intervention will involve one session of maximal eccentric exercise of the knee extensor muscles (quadriceps) of the right leg. During the 24-hour period preceding the intervention, participants will be asked to refrain from any for of moderate-vigorous physical activity or exercise. Participants will perform 30 sets of 10 repetitions of maximal isokinetic eccentric knee extensions at 60 degrees/second with 1-minute of rest between each set. Before completing the exercise bout, each participant will be asked to remain in a seated position (resting) for 30-minutes and then provide a skeletal muscle biopsy using the modified Bergstrom with suction muscle biopsy technique from the vastus lateralis on the right leg. This will be done for the baseline assessment of 5 myokines including apelin, fibroblast growth factor-21, irisin, interleukin-6, and interleukin-15. Then the participants will complete the exercise bout as described above. They will then rest quietly in the laboratory for 3-hours and wait for the second skeletal muscle biopsy to be taken following this 3-hour wait.

Study Type

Interventional

Enrollment (Estimated)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3T2N2
        • Recruiting
        • Applied Research Centre, Faculty of Kinesiology, University of Manitoba
        • Contact:
        • Contact:
        • Principal Investigator:
          • Stephen M Cornish, Ph.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18-35 years old
  • healthy
  • recreationally active (>/= 150 minutes of moderate to vigorous physical activity per week for at least the past three months)

Exclusion Criteria:

  • "yes" answer to the Get Active Questionnaire which screens for health conditions that may affect exercise ability

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Eccentric Exercise
300 repetitions of isokinetic dynamometer eccentric knee extensions.
Procedure: Eccentric resistance-exercise
Each participant will complete 300 repetitions of eccentric knee extensions using an isokinetic dynamometer after a baseline skeletal muscle biopsy is taken. Three hours following this, a second muscle biopsy will be taken to evaluate the changes in the dependent variables being measured (myokines).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Apelin
Time Frame: Baseline and 3-hours post-exercise
Concentration of apelin in skeletal muscle tissue
Baseline and 3-hours post-exercise
Fibroblast growth factor-21
Time Frame: Baseline and 3-hours post-exercise
Concentration of fibroblast growth factor-21 in skeletal muscle tissue
Baseline and 3-hours post-exercise
Irisin
Time Frame: Baseline and 3-hours post-exercise
Concentration of irisin in skeletal muscle tissue
Baseline and 3-hours post-exercise
Interleukin-6
Time Frame: Baseline and 3-hours post-exercise
Concentration of interleukin-6 in skeletal muscle tissue
Baseline and 3-hours post-exercise
Interleukin-15
Time Frame: Baseline and 3-hours post-exercise
Concentration of interleukin-15 in skeletal muscle tissue
Baseline and 3-hours post-exercise

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body mass
Time Frame: Baseline
Body mass in kilograms
Baseline
Body height
Time Frame: Baseline
Body height in meters
Baseline
Body mass index
Time Frame: Baseline
Body mass index in kg/m^2
Baseline
Fat mass
Time Frame: Baseline
Fat mass in kilograms
Baseline
Fat free mass
Time Frame: Baseline
Fat free mass in kilograms
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Manitoba

Investigators

  • Principal Investigator: Stephen M Cornish, PhD, University of Manitoba

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2024

Primary Completion (Estimated)

July 31, 2025

Study Completion (Estimated)

November 1, 2025

Study Registration Dates

First Submitted

July 5, 2024

First Submitted That Met QC Criteria

November 4, 2024

First Posted (Estimated)

November 7, 2024

Study Record Updates

Last Update Posted (Estimated)

November 7, 2024

Last Update Submitted That Met QC Criteria

November 4, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 60484

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe